Stakeholders pitched the Drug Enforcement Administration on differing guardrails the agency could include in a special telehealth registration system, expected to be proposed this fall, during telemedicine listening sessions held by DEA earlier this month. A key tension that arose was how involved DEA should get in restricting clinical decision making and prescribing authority by installing number-based caps on controlled substances prescribed per telehealth provider. The American Telemedicine Association argued DEA should not be getting into the weeds of clinical...